Similar articles for PMID: 23585514

Year	Number of Results
1999	2
2001	1
2006	1
2007	2
2008	5
2009	6
2010	10
2011	12
2012	20
2013	22
2014	18
2015	10
2016	1
2017	5
2018	1
2020	3
2022	1
2023	1
2024	0

1

Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives.

Milani A, Sangiolo D, Montemurro F, Aglietta M, Valabrega G. Milani A, et al. Ann Oncol. 2013 Jul;24(7):1740-1748. doi: 10.1093/annonc/mdt133. Epub 2013 Apr 12. Ann Oncol. 2013. PMID: 23585514 Free article. Review.

2

[Anti-HER2 vaccines: The HER2 immunotargeting future?].

Ladjemi MZ, Jacot W, Pèlegrin A, Navarro-Teulon I. Ladjemi MZ, et al. Pathol Biol (Paris). 2011 Jun;59(3):173-82. doi: 10.1016/j.patbio.2009.04.002. Epub 2009 May 28. Pathol Biol (Paris). 2011. PMID: 19481373 Free article. Review. French.

3

Trastuzumab-containing regimens for metastatic breast cancer.

Balduzzi S, Mantarro S, Guarneri V, Tagliabue L, Pistotti V, Moja L, D'Amico R. Balduzzi S, et al. Cochrane Database Syst Rev. 2014 Jun 12;2014(6):CD006242. doi: 10.1002/14651858.CD006242.pub2. Cochrane Database Syst Rev. 2014. PMID: 24919460 Free PMC article. Review.

4

A systematic review of dual targeting in HER2-positive breast cancer.

Kümler I, Tuxen MK, Nielsen DL. Kümler I, et al. Cancer Treat Rev. 2014 Mar;40(2):259-70. doi: 10.1016/j.ctrv.2013.09.002. Epub 2013 Sep 11. Cancer Treat Rev. 2014. PMID: 24080156 Review.

5

Beyond trastuzumab and lapatinib: new options for HER2-positive breast cancer.

Zardavas D, Cameron D, Krop I, Piccart M. Zardavas D, et al. Am Soc Clin Oncol Educ Book. 2013. doi: 10.14694/EdBook_AM.2013.33.e2. Am Soc Clin Oncol Educ Book. 2013. PMID: 23714441 Free article. Review.

6

A phase II study of lapatinib for brain metastases in patients with HER2-overexpressing breast cancer following trastuzumab based systemic therapy and cranial radiotherapy: subset analysis of Japanese patients.

Iwata H, Narabayashi M, Ito Y, Saji S, Fujiwara Y, Usami S, Katsura K, Sasaki Y. Iwata H, et al. Int J Clin Oncol. 2013 Aug;18(4):621-8. doi: 10.1007/s10147-012-0444-2. Epub 2012 Jul 19. Int J Clin Oncol. 2013. PMID: 23011099 Clinical Trial.

7

A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancer.

Chen G, Gupta R, Petrik S, Laiko M, Leatherman JM, Asquith JM, Daphtary MM, Garrett-Mayer E, Davidson NE, Hirt K, Berg M, Uram JN, Dauses T, Fetting J, Duus EM, Atay-Rosenthal S, Ye X, Wolff AC, Stearns V, Jaffee EM, Emens LA. Chen G, et al. Cancer Immunol Res. 2014 Oct;2(10):949-61. doi: 10.1158/2326-6066.CIR-14-0058. Epub 2014 Aug 12. Cancer Immunol Res. 2014. PMID: 25116755 Free PMC article. Clinical Trial.

8

A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer.

Larsen PB, Kümler I, Nielsen DL. Larsen PB, et al. Cancer Treat Rev. 2013 Nov;39(7):720-7. doi: 10.1016/j.ctrv.2013.01.006. Epub 2013 Mar 5. Cancer Treat Rev. 2013. PMID: 23481218 Review.

9

HER2-Positive Breast Cancer Immunotherapy: A Focus on Vaccine Development.

Arab A, Yazdian-Robati R, Behravan J. Arab A, et al. Arch Immunol Ther Exp (Warsz). 2020 Jan 9;68(1):2. doi: 10.1007/s00005-019-00566-1. Arch Immunol Ther Exp (Warsz). 2020. PMID: 31915932 Free PMC article. Review.

10

Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivo.

Morse MA, Wei J, Hartman Z, Xia W, Ren XR, Lei G, Barry WT, Osada T, Hobeika AC, Peplinski S, Jiang H, Devi GR, Chen W, Spector N, Amalfitano A, Lyerly HK, Clay TM. Morse MA, et al. Int J Cancer. 2010 Jun 15;126(12):2893-903. doi: 10.1002/ijc.24995. Int J Cancer. 2010. PMID: 19856307 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

101 results

Results by year